Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Formycon Believes Itself Among Frontrunners For Mammoth Keytruda Opportunity

German Firm Distances Comparisons With Saturated Humira Development Pool

Executive Summary

On the back of early success with its biosimilar to Lucentis (ranibizumab), Formycon has looked further into the future and divulged details on the set-to-be competitive race to develop a biosimilar to Merck & Co’s 10bn ($10.9bn) PD-1 inhibitor Keytruda (pembrolizumab).

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts